Epigenetic Changes Drive Cellular Senescence—New Targets for Senotherapy Emerge

Cellular senescence—when cells stop dividing but don't die—is a major driver of age-related tissue dysfunction. A new review synthesizes evidence showing that epigenetic changes (chemical modifications to DNA and histones that control gene activity without altering the genetic code) are not just consequences but active controllers of senescence. Key findings include how DNA methylation patterns shift to lock cells into a senescent state, and how histone modifications regulate the senescence-associated secretory phenotype (SASP) that spreads inflammation. Importantly, some epigenetic marks are reversible, making them attractive drug targets. Early-stage compounds that modify these marks have shown promise in lab models, either by pushing senescent cells toward death (senolytics) or by suppressing harmful SASP signals without killing cells. The review emphasizes precision: different senescent cell types have distinct epigenetic signatures, so effective therapies will likely need to be tailored. While most data come from cell culture and animal studies, the mechanistic clarity provides a roadmap for clinical translation.